The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
BINGO its so good to read this, it is what so many posts are missing, quote RMM3383 "once we have a successful drug (or what looks like a successful drug) then the science no longer holds centre stage but the commercial negotiations become paramount."
For me this is exactly where we are, all of the continuous posts about the science however informative are not at the business end of this next deal stage... SAR have entered the stage of the boys who will negotiate the future of this holding which if it is Dr Parker and his commercial and legals team I have maximum confidence in them.
As for the pending year end results, the nature of this business requires expenditure on R&D so they will show less in the bank and expenditure with little revenue...so don't be dismayed by this, its a good thing providing they are spending it in the right areas that will attract the buyers... the strategic model requires expenditure to licence at pre-clinical or early clinical stages at which point..... we are back to the point of the negotiations stage being paramount in realizing the true value of whichever the commodity is that SAR are selectively taking to the market.
SAR are full-filling their strategic plan and focusing on their core business activities..... the question that I am sure will be answered, governed by any disclosure restrictions, at the Investor Presentation is the future projections and where and what licensed commodity will they be brokering with the big pharmas.
I’m sure that many of our questions will be answered in the next couple of weeks
There is also an opportunity to ask all of your individual questions and concerns on the investor meet platform, and the BOD will endeavour to answer every question that they can. In my experience they have been pretty good at providing answers. GLA, not long now!
RV - Thanks for you support. I only tend to post when I think I've got something to add. For the record this is where I'm at today.
In the year 0002 BC (Before Covid) I attended an AGM where I expressed concern that in respect of TYK2 we could be spread too thinly across the multiple indications that 1801/2 could address. Tim’s response was that we only needed to be successful in one. Having now had a number of years to ponder that response and given that we are now very close to a CTA the key question for me over the next few weeks is just what that initial indication is going to be. Lots has been posted on the patents and possible uses for 1801 and 1802 and my valuations have not ignored the breadth of the possibilities. However, just for balance we need to take into account that once we have a successful drug (or what looks like a successful drug) then the science no longer holds centre stage but the commercial negotiations become paramount. Dr Parker is no fool when it comes to negotiation and in the other NED’s he has serious support to call upon. The declared model for SAR is to licence at pre-clinical or early clinical and so far we’ve not been told anything different. What I’ll be looking for on the 2nd November is clarity around the CTA for 1801 (yes, we know that Covid has caused all sorts of problems for trials, lab space etc) after which we can start to think about timescales and revised valuations. Given how long we’ve been here I think the timescales are shortening but its not going to be Monday for a T/O. SAR have always tried to release some good news before the AGM for obvious reasons and I don’t think this year will be any different. GLA
RMM- guess he told his partner 2 inches was massive as well.
I’ve missed your well informed posts RMM. One of the most balanced posters we have on this board
So, 5% down is 'massive' which means that the rise we had earlier in the week was even more 'massive'. Wow, I need to revisit my perspective on terminology and completely revamp my valuation models. Could be a long day. On the other hand I've just bought a Euromillions ticket. If I get a massive win then the whole lot goes on SAR. Meanwhile I'll concur with Thoth and wait for the presentation from the BoD which will be far more interesting. GLA